Reassessing pembrolizumab dosing in NSCLC for methodological and clinical accuracy - Author's reply

Geeske F Grit1, Peter G M Mol2, Doranne Hilarius3

  • 1Dutch Institute for Clinical Auditing, Leiden, The Netherlands; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.

Abstract

No abstract available in PubMed .

Related Concept Videos